RecruitingPlasma Cell Myeloma
Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This early phase I trial studies how well loratadine works in reducing granulocyte-colony stimulating factor (G-CSF) induced bone pain in patients with multiple myeloma who are undergoing stem cell mobilization. Loratadine is an antihistamine that may help to reduce or control bone pain during the process of stem cell collection in patients with multiple myeloma.
Sponsor: Rutgers, The State University of New Jersey
You may qualify if…
- ✓ Patient must be able to provide informed consent
- ✓ Patients with confirmed diagnosis of multiple myeloma
- ✓ Able to swallow and retain oral medication
- ✓ All ethnic groups are eligible
You may not qualify if…
- ✕ Non-English speaking person
- ✕ Patients undergoing haploidentical allogeneic hematopoietic stem cell transplant
- ✕ Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds
- ✕ Any medical complications or conditions that would, in the investigator's judgement, interfere with full participation in the study
- ✕ On therapeutic dose of aspirin (doses greater than 81 mg) within 7 days prior to the start of the study
Where it's recruiting
New Jersey
New Brunswick
Source: ClinicalTrials.gov · NCT04211259 · last updated 2026-05-29